# itRECIST (response criteria for injected immunotherapy)

Source: https://onco.cc/terms/itrecist/  
OnCo record `itrecist` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

itRECIST adapts the scan-measuring rules for trials in which the immunotherapy is injected straight into a tumour, so that injected and uninjected tumours are tracked separately.

## Summary

Goldmacher and colleagues (Journal of Clinical Oncology 2020) published itRECIST, response criteria for intratumoural immunotherapy in solid tumours. The CDISC oncology response codelist holds it as itRECIST Goldmacher 2020. No abstract was available to read, so this record states only what the title and the codelist say: it is a RECIST-based set of criteria for treatments injected into tumours.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: itRECIST; intratumoral RECIST; intratumoural RECIST

## Sources

- Goldmacher et al., Response criteria for intratumoral immunotherapy in solid tumors: itRECIST (J Clin Oncol 2020): https://doi.org/10.1200/jco.19.02985
- NCI Thesaurus C179781, itRECIST Goldmacher 2020 Oncology Response Criteria: https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C179781

## Connected records

- terms: [iRECIST (response criteria for immunotherapy trials)](https://onco.cc/terms/irecist/), [RECIST](https://onco.cc/terms/recist/)
- technologies: [Intratumoural gene electrotransfer (IL-12 plasmid)](https://onco.cc/technologies/il12-electroporation/)

---
JSON: https://onco.cc/api/v1/entities/itrecist.json